Barclays PLC Obs Eva Sa Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
BUY
$1.34 - $2.08 $452 - $703
338 Added 0.82%
41,624 $67,000
Q1 2022

May 16, 2022
SELL
$1.1 - $2.17 $21,963 - $43,328
-19,967 Reduced 32.6%
41,286 $62,000
Q4 2021

Feb 14, 2022
SELL
$1.99 - $3.1 $7,227 - $11,259
-3,632 Reduced 5.6%
61,253 $121,000
Q3 2021

Nov 09, 2021
SELL
$2.47 - $3.34 $71,847 - $97,153
-29,088 Reduced 30.95%
64,885 $201,000
Q2 2021

Aug 13, 2021
SELL
$2.56 - $3.35 $13,463 - $17,617
-5,259 Reduced 5.3%
93,973 $284,000
Q1 2021

May 13, 2021
SELL
$2.01 - $5.05 $149,952 - $376,745
-74,603 Reduced 42.92%
99,232 $322,000
Q4 2020

Feb 11, 2021
BUY
$1.89 - $2.55 $248,580 - $335,386
131,524 Added 310.85%
173,835 $361,000
Q3 2020

Nov 12, 2020
BUY
$2.46 - $6.15 $104,085 - $260,212
42,311 New
42,311 $105,000
Q2 2020

Aug 12, 2020
SELL
$2.01 - $5.95 $765 - $2,266
-381 Closed
0 $0
Q1 2020

May 13, 2020
SELL
$1.87 - $4.47 $4,914 - $11,747
-2,628 Reduced 87.34%
381 $1,000
Q4 2019

Feb 10, 2020
BUY
$2.48 - $8.1 $6,043 - $19,739
2,437 Added 426.05%
3,009 $11,000
Q3 2019

Nov 14, 2019
SELL
$8.22 - $11.2 $134,306 - $182,996
-16,339 Reduced 96.62%
572 $5,000
Q2 2019

Aug 14, 2019
BUY
$10.05 - $14.25 $161,664 - $229,225
16,086 Added 1949.82%
16,911 $192,000
Q1 2019

May 15, 2019
SELL
$11.82 - $14.48 $109,843 - $134,562
-9,293 Reduced 91.85%
825 $10,000
Q4 2018

Feb 14, 2019
BUY
$10.8 - $17.94 $83,926 - $139,411
7,771 Added 331.1%
10,118 $128,000
Q3 2018

Nov 14, 2018
BUY
$10.92 - $18.18 $20,169 - $33,578
1,847 Added 369.4%
2,347 $42,000
Q2 2018

Aug 14, 2018
BUY
$10.0 - $17.87 $5,000 - $8,935
500 New
500 $8,000

Others Institutions Holding OBSV

# of Institutions
2
Shares Held
88K
Call Options Held
0
Put Options Held
0
View Full List

About ObsEva SA

OBSV Quotes by TradingView
  • Ticker OBSV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,499,200
  • Description
  • ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...
More about OBSV
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email